Enzalutamide in metastatic prostate cancer before chemotherapy
Androgen Receptor Antagonists
Antineoplastic Agents, Hormonal
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov number, NCT01212991.).